MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL

File: 123096_sep96_decls28_0028.txt
Page: 0028
Total Pages: 40

Subject: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003203

Folder Title: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                                                     

Document Number:          1

Folder Seq  #:         47





                                        UNCLASSIFIED








          (1000 mg initially, followed by 750 mg bid) or doxycycline (200
          mg initially, followed by 100 mg q 12 hrs). Supportive therapy
          for shock, fluid volume deficit, and adequacy of airway may all
          be needed.




            vaccine. A licensed, alum-precipitated, preparation of
          purified Bacillus anthkacis protective antigen (PA) has been
          shown to be effective in preventing or significantly reducing
          the incidence of inhalation anthrax. Limited human data
          suggest that after completion of the first three doses of the
          recommended six-dose primary series protection against both
          cutaneous and inhalation anthrax is afforded. Studies in
          rhesus monkeys indicate that good protection is afforded after
          two doses (10-16 days apart) for up to 2 years. It is likely
          that two doses in humans is protective as well, but there is
          too little information to draw firm conclusions. As with all
          vaccines, the degree of protection depends upon the magnitude
          of the challenge dose; vaccine-induced protection is
          undoubtedly overwhelmed by extremely high spore challenge.

            In the present setting, three doses of the vaccine is
          recommended for prophylaxis against inhalation anthrax.
          Contraindications for use are sensitivity to vaccine components
          (formalin, alum, benzethonium chloride) and/or history of
          clinical anthrax. Reactogenicity is mild to moderate: up to
          6% of recipients will experience mild discomfort at the
          innoculation site for up to 72 hours (tenderness, erythema,
          edema, pruritus), while a smaller proportion (I%) will
          experience more severe local reactions (potentially limiting
          use of the extremity for 1-2 days); modest systemic reactions
          (myalgia, malaise, low-grade fever) are uncommon, and severe
        systemic reactions (anaphylaxis, which precludes additional
          vaccination) are rare. The vaccine should be stored at
          refrigerator temperature (@ frozen).




            Choice of antibiotics for prophylaxis is guided by the same
          principles as that for treatment; i.e., it is relatively easy
          to produce a penicillin-resistant organism in the laboratory,



                                          6



                                         UNCLASSIFIED

Document 40 f:/Week-36/BX003203/MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL/medical defense against biological material:12179609282229
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Folder Seq # = 47
Subject = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 17-DEC-1996